Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT05776134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Lead sponsor
Kite, A Gilead Company
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, mantle cell lymphoma